Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | LPL | P06858 | 8/20 | 0.55 |
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.55 |
| ▸ | RARB | P10826 | 5/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.54 |
| ▸ | RARA | P10276 | 1/20 | 0.43 |
| ▸ | RARG | P13631 | 1/20 | 0.43 |
| ▸ | MPL | P40238 | 3/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6557463 | 0.96 | LPL (0.62) | CA1CA2LPLLIPGRARB | |
| SCHEMBL8767993 | 0.91 | LPL (0.59) | CA1CA2LPLLIPGRARB | |
| SCHEMBL9493977 | 0.87 | LPL (0.62) | CA1CA2LPLLIPGRARB | |
| SCHEMBL10975470 | 0.83 | RARB (0.61) | CA1CA2RARBRARARARG | |
| SCHEMBL12696478 | 0.83 | CA1 (0.61) | CA1CA2LPLLIPGRARB | |
| SCHEMBL14175170 | 0.82 | RARB (0.59) | RARBRARARARGMPLS1PR1 | |
| SCHEMBL9662908 | 0.82 | RARB (0.59) | CA1CA2RARBRARARARG | |
| SCHEMBL10978118 | 0.80 | RARB (0.58) | RARBRARARARGMPLS1PR1 | |
| SCHEMBL10981036 | 0.80 | RARB (0.66) | RARBRARARARGMPL | |
| SCHEMBL10986630 | 0.80 | RARB (0.58) | CA1CA2RARBRARARARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1126006-B1 | Liquid crystal compounds, liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2009-03-04 | — | — | EP | disclosed |
| US-6569505-B2 | Holography | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2003-05-27 | — | — | US | disclosed |
| US-20020142108-A1 | Liquid crystal compounds, liquid crystal medium and liquid crystal display | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-10-03 | — | — | US | disclosed |
| EP-1126006-A2 | Liquid crystal compounds, liquid crystal medium and liquid crystal display | MERCK PATENT GmbH (DE) | 2001-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142108-A1 | Liquid crystal compounds, liquid crystal medium and liquid crystal display | CDC25C, TEC, PLK1 | CA1 311/4885CA2 1147/4885LPL 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.